Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

Snoep, 2007, Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis, Am Heart J, 154, 221, 10.1016/j.ahj.2007.04.014 Siller-Matula, 2007, Thienopyridines in cardiovascular disease: focus on clopidogrel resistance, Thromb Haemost, 97, 385, 10.1160/TH06-08-0420 Angiolillo, 2008, Current antiplatelet therapies: benefits and limitations, Am Heart J, 156, S3, 10.1016/j.ahj.2008.06.003 Gladding, 2008, Antiplatelet drug nonresponsiveness, Am Heart J, 155, 591, 10.1016/j.ahj.2007.12.034 Savi, 2000, Identification and biological activity of the active metabolite of clopidogrel, Thromb Haemost, 84, 891, 10.1055/s-0037-1614133 Pereillo, 2002, Structure and stereochemistry of the active metabolite of clopidogrel, Drug Metab Dispos, 30, 1288, 10.1124/dmd.30.11.1288 Small, 2008, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel, J Clin Pharmacol, 48, 475, 10.1177/0091270008315310 Lotfi, 2008, Am Heart J, 155, 954, 10.1016/j.ahj.2007.12.009 Li, 2004, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities, Drug Metab Dispos, 32, 821, 10.1124/dmd.32.8.821 Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Gilard, 2006, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x Ishizaki, 1999, Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole, Aliment Pharmacol Ther, 13, 27, 10.1046/j.1365-2036.1999.00022.x Cairns, 2008, Clopidogrel resistance: more grist for the mill, J Am Coll Cardiol, 51, 1935, 10.1016/j.jacc.2008.01.051 Gurbel, 2007, Platelet function monitoring in patients with coronary artery disease, J Am Coll Cardiol, 50, 1822, 10.1016/j.jacc.2007.07.051 Manolopoulos, 2008, Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents, Platelets, 19, 134, 10.1080/09537100701708498 Sudo, 2003, Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets, Platelets, 14, 381, 10.1080/09537100310001598819 Judge, 2008, The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses, Platelets, 19, 125, 10.1080/09537100701694144 Bonello, 2007, Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events, J Thromb Haemost, 5, 1630, 10.1111/j.1538-7836.2007.02609.x Bonello, 2008, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study, J Am Coll Cardiol, 51, 1404, 10.1016/j.jacc.2007.12.044 Kleiman, 2008, Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?, J Am Coll Cardiol, 51, 1412, 10.1016/j.jacc.2008.02.026 Siller-Matula, 2008, Calcium channel blockers reduce the antiplatelet effect of clopidogrel, J Am Coll Cardiol, 52, 1557, 10.1016/j.jacc.2008.07.055 Siller-Matula, 2008, Reproducibility and standardised reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay, Platelets, 19, 551, 10.1080/09537100802272634 Morel, 2007, Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis, Thromb. Haemost., 98, 896, 10.1160/TH07-03-0188 Seyfert, 2007, Variables influencing Multiplate (TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals, Platelets, 18, 199, 10.1080/09537100600944277 Sibbing, 2008, Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment, Thromb Haemost, 99, 121, 10.1160/TH07-07-0478 Toth, 2006, Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood, Thromb Haemost, 96, 781, 10.1160/TH06-05-0242 Penz, 2007, Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques, Thromb Haemost, 97, 435, 10.1160/TH06-07-0415 Mueller, 2007, Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate(R) analyzer-comparison with two flow cytometric methods, Thromb Res, 121, 249, 10.1016/j.thromres.2007.03.022 Abelo, 2000, Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes, Drug Metab Dispos, 28, 966 Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC Saw, 2007, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097 Angiolillo, 2007, Clopidogrel-statin interaction: myth or reality?, J Am Coll Cardiol, 50, 296, 10.1016/j.jacc.2007.04.041